The biotechnology industry has become increasingly adept at celebrating speed. Investor presentations highlight accelerated site activation, compressed study timelines and rapid first-patient-in milestones as indicators of execution. Yet beneath these metrics lies an uncomfortable truth: much of this apparent speed is an illusion.

Nowhere is this more evident than in clinical trial contracting. What appears to be rapid progress during early development frequently creates hidden operational debt that surfaces later as programmes expand. The result is not faster drug development, but greater unpredictability, higher costs and delayed patient access.

This phenomenon reflects a broader principle recognised in systems engineering and organisational science: optimising individual tasks rarely optimises the performance of the entire system ^[1][2].

For emerging biotechnology companies, the temptation is understandable. Lean legal departments face intense pressure to demonstrate momentum. Executing a handful of Clinical Trial Agreements (CTAs) during Phase I or Phase II appears manageable. However, success creates its own challenge. A global Phase III programme may require thousands of agreements across dozens of countries, each governed by different legal frameworks, institutional policies and regulatory requirements.

At that point, contracting ceases to be an administrative activity and becomes a critical determinant of operational performance.

Unfortunately, many organisations discover that they have built speed without scalability.
The technology industry’s famous mantra of “move fast and break things” succeeded because companies such as Meta invested heavily in sophisticated engineering infrastructure capable of absorbing mistakes and recovering rapidly. Clinical development offers no such luxury. Every protocol deviation, contractual inconsistency or governance failure introduces risks that cannot simply be patched in the next software release.

Biotechnology companies often attempt to preserve the appearance of momentum by negotiating contracts independently, accepting inconsistent language, maintaining multiple document versions and relying upon individual institutional knowledge rather than standardised processes. Initially, this feels productive. In reality, it creates increasing organisational complexity that eventually overwhelms the legal function.

Psychologists describe this tendency as the planning fallacy—our consistent tendency to underestimate complexity while overestimating our ability to execute future work efficiently ^[3]. Organisational researchers similarly demonstrate that growing process variability inevitably increases system unpredictability and reduces overall performance ^[4].

The financial consequences are substantial.

Estimates consistently suggest that delays in pharmaceutical development can destroy enormous commercial value. Depending on therapeutic area and product profile, even a single day’s delay to market has been estimated to cost sponsors hundreds of thousands to several million dollars in lost lifetime revenue ^[5]. Multi-month delays can translate into well over $100 million in lost commercial opportunity for high-value medicines ^[6].

More importantly, delays carry an equally significant human cost.

Every unnecessary week spent resolving contracting disputes postpones patient recruitment and delays access to potentially life-saving therapies. While commercial timelines dominate boardroom discussions, patients experience those same delays as months without new treatment options.

The irony is that many of these delays originate from decisions intended to accelerate delivery.

Quality and speed are frequently presented as competing priorities. They are not.

In reality, quality is speed.

Every inconsistent contract clause, every uncontrolled document revision and every unnecessary negotiation creates friction that compounds as programmes scale. Errors discovered late are dramatically more expensive to correct than those prevented through better design ^[7]. This principle has been recognised for decades in manufacturing through Deming’s work on quality management and increasingly underpins Quality by Design approaches within pharmaceutical development ^[8].

The lesson extends well beyond contracting.

Clinical development increasingly relies upon surrogate endpoints to accelerate approvals. While surrogate measures may reduce trial duration compared with overall survival endpoints, they also introduce uncertainty regarding the true magnitude of patient benefit ^[9]. The objective is not simply to move faster but to make better decisions about where speed genuinely creates value and where it merely creates risk.

Contracting deserves the same disciplined thinking.

The organisations consistently delivering predictable global trials are not necessarily those negotiating individual agreements fastest. They are those that have invested in building a contracting engine.

That engine begins with planning. Understanding standard market positions across key jurisdictions avoids reinventing contractual language for every study and enables negotiation strategies based upon evidence rather than precedent within individual organisations.

It continues with empowerment. Rather than drafting every agreement, legal teams should increasingly focus on creating robust templates, negotiation playbooks, standard fallback clauses and governance frameworks. This allows clinical operations teams to resolve routine issues while reserving specialist legal expertise for genuinely complex decisions.

Technology provides another critical layer. Modern Contract Lifecycle Management (CLM) platforms standardise workflows, improve version control, centralise institutional knowledge and automate repetitive activities. Published industry analyses suggest that mature CLM implementation can reduce contract cycle times by 20–30%, while AI-enabled workflows have demonstrated even greater improvements in investigator onboarding and document review efficiency ^[10][11].

Equally important is knowledge codification.

Too many organisations depend upon individual experience residing within specific lawyers or contract managers. When those individuals leave, valuable institutional knowledge disappears with them. Centralised repositories, structured playbooks and continuously updated template libraries convert individual expertise into organisational capability.

This reflects an important distinction between operating and building.

Most legal teams operate today’s trials exceptionally well. Far fewer simultaneously build the infrastructure required to support tomorrow’s pipeline.

As biotechnology companies mature, this distinction becomes decisive.

A trial should never be viewed as an isolated project. Every agreement negotiated should strengthen the organisation’s future contracting capability. Every difficult negotiation should improve standard clauses. Every jurisdictional lesson should become part of institutional knowledge.

The objective is no longer simply executing contracts.

It is creating a scalable operating system for clinical development.

Ultimately, speed is not measured by how quickly the first site opens. It is measured by how predictably an entire global programme progresses from protocol approval to database lock without unnecessary legal friction, operational surprises or avoidable delays.

The illusion of speed focuses attention on visible milestones.

Real speed is quieter.

It is built through disciplined processes, standardised legal frameworks, organisational learning and investments that make every subsequent trial faster than the last.

For organisations serious about accelerating drug development, the message is straightforward. Align legal strategy with site start-up planning from the outset. Build contracting capability rather than simply delivering contracts. Invest equally in today’s execution and tomorrow’s infrastructure.

Because in clinical development, the fastest organisations are rarely those moving the quickest today.

They are the ones systematically eliminating the causes of delay before they ever occur.

References

1. Deming WE. Out of the Crisis. Cambridge (MA): Massachusetts Institute of Technology, Center for Advanced Engineering Study; 1986. ISBN: 9780911379018. URL: https://mitpress.mit.edu/ 
2. Goldratt EM, Cox J. The Goal: A Process of Ongoing Improvement. 30th Anniversary ed. Great Barrington (MA): North River Press; 2014. ISBN: 9780884271951.
3. Kahneman D, Tversky A. Intuitive prediction: biases and corrective procedures. In: Kahneman D, Slovic P, Tversky A, editors. Judgment Under Uncertainty: Heuristics and Biases. Cambridge: Cambridge University Press; 1982. p. 414–421. 
4. March JG. Exploration and exploitation in organizational learning. Organization Science. 1991;2(1):71-87. doi:10.1287/orsc.2.1.71. https://doi.org/10.1287/orsc.2.1.71 
5. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012. https://doi.org/10.1016/j.jhealeco.2016.01.012. PubMed: https://pubmed.ncbi.nlm.nih.gov/26928437/ 
6. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166. https://doi.org/10.1001/jama.2020.1166. PubMed: https://pubmed.ncbi.nlm.nih.gov/32125404/ 
7. Juran JM, Godfrey AB, editors. Juran’s Quality Handbook. 7th ed. New York: McGraw-Hill; 2017.
8. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009. https://www.ich.org/page/quality-guidelines
9. Prasad Vinay, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review. JAMA Internal Medicine. 2015;175(8):1389-1398. https://doi.org/10.1001/jamainternmed.2015.2829. 
10. World Commerce & Contracting. The ROI of Commercial & Contract Management. WorldCC; 2023. https://www.worldcc.com/ 
11. Deloitte. AI-enabled Contract Lifecycle Management in Life Sciences. Deloitte Insights. 2024. https://www2.deloitte.com/